FGF9 and neoplasm: FGF9 with higher expression remained a notable indicator of shorter survival in stage II (30.6 months vs. 64.9 months, P < 0.001, n=56) and stage III (29.7 months vs. 58.9 months, P < 0.001, n=92) (Figure 3) by tumour stage stratification in GC.